A national prospective cohort study of SARS/COV2 pandemic outcomes in the U.S.: The CHASING COVID Cohort

McKaylee Robertson[1], Sarah Kulkarni[1], Amanda Berry[1], Chloe Mirzayi[1,2], Andrew Maroko[1,3], Rebecca Zimba[1], Drew Westmoreland[1], Christian Grov[1,4], Angela Parcesepe[1,5,6], Levi Waldron[1,2], and Denis Nash[1,2] for the CHASING COVID Cohort (C^3) Study

Affiliations:

[1]Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY); New York City, New York USA

[2]Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY); New York City, New York USA

[3]Department of Environmental, Occupational, and Geospatial Health Sciences, Graduate School of Public Health and Health Policy, City University of New York (CUNY); New York City, New York USA

[4]Department of Community Health and Social Sciences, Graduate School of Public Health and Health Policy, City University of New York (CUNY); New York City, New York USA

[5]Department of Maternal and Child Health, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA

[6] Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

WORD COUNT (ABSTRACT): 322

WORD COUNT (BODY): 4,003

CONFLICT OF INTEREST: None declared

Keywords: COVID-19; serology, seroconversion, asymptomatic infection, physical distancing; natural history study, epidemiologic study

CORRESPONDING AUTHOR:

Denis Nash, Ph.D., MPH
55 W. 125th St.
New York, NY USA 10027.
Phone: +1-(917) 740-8714
Fax: +1-866-792-7203
Email: denis.nash@sph.cuny.edu

ABSTRACT

Introduction: The Chasing COVID Cohort (C^3) study is a US-based, geographically and socio-demographically diverse sample of adults (18 and older) enrolled into a prospective cohort study during the upswing of the U.S. COVID-19 pandemic.

Methods: We used internet-based strategies to enroll C^3 participants beginning March 28th, 2020. Following baseline questionnaire completion, study participants will be contacted monthly (for 6 months) to complete assessments of engagement in non-pharmaceutical interventions (e.g., use of cloth masks, avoiding large gatherings); COVID-19 symptoms; SARS/COV2 testing and diagnosis; hospitalizations; healthcare access; and uptake of health messaging. Dried blood spot (DBS) specimens will be collected at the first follow-up assessment (last week of April 2020) and at month 3 (last week of June 2020) and stored until a validated serologic test is available.

Results: As of April 20, 2020, the number of people that completed the baseline survey and provided contact information for follow-up was 7,070. Participants resided in all 50 US states, the District of Columbia, Puerto Rico, and Guam. At least 24% of participants were frontline workers (healthcare and other essential workers). Twenty-three percent (23%) were 60+ years, 24% were Black or Hispanic, 52% were men, and 52% were currently employed. Nearly 20% reported recent COVID-like symptoms (cough, fever or shortness of breath) and a high proportion reported engaging in non-pharmaceutical interventions that reduce SARS/COV2 spread (93% avoided groups >20, 58% wore masks; 73% quarantined). More than half (54%) had higher risk for severe COVID-19 illness should they become infected with SARS/COV2 based on age, underlying health conditions (e.g., chronic lung disease), or daily smoking.

Discussion: A geographically and socio-demographically diverse group of participants was rapidly enrolled in the C^3 during the upswing of the SARS/COV2 pandemic. Strengths of the C^3

include the potential for direct observation of, and risk factors for, seroconversion and incident COVID disease (among those with or without antibodies to SARS/COV2) in areas of active transmission.

INTRODUCTION

The Coronavirus Disease 2019 (COVID-19) pandemic has dramatically transformed life across the entire United States, resulting in medical and economic challenges and threats for many households and communities. The earliest research efforts have focused on understanding the clinical course of COVID-19 and the most effective ways of treating people with severe symptoms or illness. As the pandemic progresses, however, we must also investigate COVID-19's evolving epidemiology and the impact of non-pharmaceutical interventions (NPIs), such as physical distancing, health messaging, and testing. Researchers and public health practitioners have called for cohort studies to describe the community attack rate, as well as how attack rates are influenced by different approaches to NPI implementation.[1] Internet-based strategies, which facilitate rapid recruitment of large and diverse samples, can be leveraged to understand and inform this swiftly changing and protracted public health crisis.[2,3]

In response to the COVID-19 pandemic the CUNY Institute for Implementation Science in Population Health (ISPH) launched the Communities, Households and SARS/COV-2 Epidemiology (CHASING) COVID Cohort "C^3" study on March 28, 2020. We sought to recruit an online prospective cohort of 7,500 adults (18 years or older) in the United States (US) and US territories in order to rapidly contribute to our understanding of the spread and impact of the SARS/COV2 pandemic within households and communities. In a prospective cohort study, we will assess the impact of implementing, and relaxing, NPIs on SARS/COV2 clinical outcomes and psychosocial outcomes such as mental health, social support, and interpersonal violence.

METHODS

We aimed to rapidly enroll a geographically and socio-demographically diverse sample of adult participants residing in the US and US territories. We applied internet-based strategies

that have been demonstrated to be effective for recruiting and following large and geographically diverse online cohorts.[2–4]

Cohort Eligibility and Recruitment

Persons aged 18 years and above who resided in the US or US territories were eligible to join the study. Study participants were recruited via social media platforms (e.g., Facebook, Instagram, and Scruff) or via referral to the study. Anyone with knowledge of the study was allowed to invite others to participate. By tapping into personal networks of participants, we aimed to improve recruitment of persons >59 years of age, who may not be as active on social media as younger persons and thus rely more on snowball sampling methods. The study was promoted as a way for participants to contribute to understanding the COVID-19 pandemic. Facebook and Instagram advertisements were developed in English and Spanish and were geographically targeted to people currently residing in the US and US territories who were 18 or older.

The C^3 had a targeted sample size of 7,500 participants. Study staff actively monitored cohort demographics and adjusted advertisement strategies as needed to recruit a more geographically and socio-demographically diverse sample. The advertisement strategies were adaptive based on the profile of participants enrolled as of a given date. For example, strategies could shift to recruit older persons if that demographic was not well-represented.

Potential participants were directed to an enrollment survey (hosted by Qualtrics) in their web browser on a computer or mobile device.[5] The consent form described the study, monthly follow-up assessments, and future study opportunities, including the possibility to receive a SARS/COV2 serologic test as part of the study. The consent form also described the incentive schedule: a drawing for $100 for the baseline survey (with 20 winners) and gift cards ranging from $5-30 for all participants for completion of subsequent surveys and antibody testing.

Enrollment and baseline assessment

Enrollment for C^3 began on March 28, 2020, at which point there were 122,000 documented COVID-19 cases and 2,200 COVID-19 deaths reported in the US.[64] Enrollment ended on April 20, 2020, when there were 783,000 persons diagnosed with SARS/COV2, including 42,000 deaths in the U.S. (Figure 1).[6]

Figure 1. Cumulative Chasing Covid Cohort Enrollment and Cumulative COVID19 Deaths in the US



Chart: CUNY ISPH • Source: New York Times and CUNY ISPH • Created with Datawrapper

Individuals who provided informed consent were then screened for eligibility via the Qualtrics survey. Eligible and consenting individuals were asked to provide an email address for future follow-up assessments. Measures included on the baseline questionnaire were derived from previously published research (e.g., *Together 5000*[2], BRFSS, and H1N1 influenza studies[7,8]) and from other researchers who had developed surveys for understanding COVID-19 (e.g., Canadian Institutes of Health Research[7] and Food Access and Food Security during COVID-19[9]). Measures were also developed *de novo* in response to the novel pandemic. We deployed a second version of the baseline questionnaire on April 9, 2020, which added questions to capture healthcare and other essential worker status. The surveys are available on the C^3 webpage (https://cunyisph.org/chasing-covid/).

Follow-up assessments

Questionnaires. Following the baseline assessment, C^3 participants will be surveyed monthly for 6-months (until September, 2020). The follow-up assessments will gather data on

symptoms, testing, hospitalizations and other time-varying factors (e.g., NPI uptake and relaxation) (see Table 1 for survey realms).

Specimen collection. At the first follow-up assessment (end of April, 2020) and the third follow-up assessment (end of June, 2020), participants will be asked to self-collect a specimen for serologic testing. Participants will be mailed dried blood spot (DBS) self-sampling kits. Using the provided lancet, they will prick the side of their finger and provide a sample of blood on the provided card. To facilitate self-sampling procedures, all participants will receive printed instructions demonstrating procedures for DBS collection and instructions to contact the study team, if they have questions.[10] DBS cards will be returned via US Postal Service (self-addressed, stamped envelope containing EBF Foil biohazard bag™) to the C^3 study laboratory (Molecular Testing Labs)[11], where they will be banked at -80ºC for future serologic testing for IgM and IgG antibodies to SARS/COV2 via a suitable validated assay. We will monitor the emerging pipeline of serology test systems.

Table 1. Realms of Measurement in the Chasing Covid Cohort

At baseline and follow-up assessments

	Baseline	Month 1 follow-up assessment
Sociodemographics	✔	
Household size and age distribution	✔	
Pre-existing/co-morbid conditions	✔	
Smoking and vaping behaviors	✔	
Employment status	✔	✔
Essential employee status[1]	✔	✔
Health care access and insurance status	✔	✔
Recent COVID-related symptoms	✔	✔
Saw or called physician/HCP for COVID-like symptoms	✔	✔
Recent COVID diagnosis	✔	✔
Recent SARS/COV2 testing	✔	✔
Recent hospitalization for COVID-like symptoms	✔	✔
NPI uptake and other precautions	✔	✔
Anxiety symptoms (GAD-7)	✔	✔
Risk perception about COVID	✔	✔
Influence of social media on COVID knowledge and beliefs	✔	✔
Trust in government to prioritize safety		✔
Serology (SARS/COV2 IgM and IgG)		✔
Food and housing security		✔
Depressive symptoms (PHQ2)		✔
Social support		✔
IPV		✔
Substance use		✔
Unhealthy drinking (Audit-C)		✔
Willingness to donate plasma to help others		✔

[1]Frontline health care workers, hospital staff, first responders, grocery clerks, delivery workers

Table: CUNY ISPH • Source: CUNY ISPH • Created with Datawrapper

Participants who do not submit a DBS card at the end of Month 1 will be sent a reminder and will be allowed to submit it at any time during follow-up. Participants will receive $20 upon returning a valid specimen to the study laboratory.

Daily symptom tracking. Monthly assessments are supplemented by voluntary daily symptom tracking via an innovative COVID-19 symptom tracker[12] that we have deployed in our cohort. The Coronavirus Pandemic Epidemiology (COPE) consortium has developed the COVID Symptom Tracker app, downloadable for free in the Apple and Android App Stores, which enables individuals to self-report information on COVID-19 exposure and infections. On first use, the app queries location, age, and core risk factors and comorbidities. Daily prompts query for updates on interim symptoms, health care visits, and COVID-19 testing results. The C^3 Study joined the COPE consortium on April 6th, allowing our cohort members who use the app to consent to share their data with us so that it can be linked to the larger C^3 cohort data. Consent to merge data from the symptom tracker app with other C^3 data is being solicited at the Month 1 follow-up assessment.

Outcomes

Incidence of SARS/COV2 infection. The cumulative incidence of SARS/COV2 infection at the end of Month 1 (~end of April, 2020) and Month 3 (~end of June, 2020) will be defined as the proportion of persons at each time point with SARS/COV2 infection as confirmed by serologic testing: IgM and/or IgG positive. For persons testing positive at Month 1, we will assume infection occurred at the midpoint between 5 days before the county's first reported SARS/COV2 diagnosis and the date of the serologic test, unless we can assign a more accurate date based on reported symptoms and/or presence of IgM/IgG. For those who test negative at Month 1 and positive at Month 3, we will assume infection occurred at the midpoint

between the two tests (if no symptoms) or 5 days before a documented report of onset of COVID-like symptoms.

Asymptomatic SARS/COV2 infection. Asymptomatic infection will be defined as a positive SARS/COV2 serologic test, with no documented report of COVID-like symptoms from prior C^3 interviews or from the COVID-19 symptom tracker app. The proportion with asymptomatic infection among persons with a positive SARS/COV2 serologic test will then be calculated as the number with asymptomatic infection divided by the total number with a positive serologic test. We will stratify our estimates of the proportion with asymptomatic infection by whether the seroconversion occurred prior to month 1 or whether seroconversion was observed in the cohort between Months 1 and 3 among those with a documented negative serologic test at Month 1.

Confirmed and possible COVID-19 disease at or prior to baseline. For SARS/COV2 seropositive persons, we will define confirmed prior COVID-19 as a self-report of symptoms consistent with COVID-19 on our symptom screener in the two weeks prior to baseline, with a date of disease onset estimated as one week prior to baseline. Those reporting COVID-19 symptoms without a serologic test will be considered possible cases of prior COVID-19.

Confirmed incident COVID-19 disease after serologic testing. For analyses to assess subsequent disease after Month 1, incident COVID-19 disease will be defined as development of new COVID-like symptoms $\geq$7 days after the first (positive or negative) SARS/COV2 serologic test result.[13] We will count new COVID-19 disease, including a self-report of COVID-like symptoms, COVID-19 diagnosis or hospitalization on the C^3 questionnaire or via the COVID-19 symptom tracker app. Severe COVID-19 disease will be defined as having been hospitalized for COVID-like symptoms.

Other outcomes. We will examine secondary outcomes such as: anxiety symptoms (Generalized Anxiety Disorder-7 [GAD-7] 7-item scale][14]), and depressive symptoms (Patient

Health Questionnaire-2 [PHQ-2][15]). We will also measure and describe the prevalence of food insecurity[9], substance use[16,17], unhealthy drinking (Alcohol Use Disorders Identification Test [AUDIT-C])[[18], and intimate partner violence (IPV).

Exposures

NPI uptake in the C^3 cohort. We will examine specific NPI uptake among C^3 cohort participants over time, and also calculate NPI uptake by creating an index. The index is a summative score of responses to survey questions about engagement in NPI actions in the two weeks prior to the survey. Each affirmative or neutral action is weighted 1 and each negative response 0, so that a higher index value indicates greater NPI uptake/engagement.

State level NPI implementation. We and others have compiled living databases of state-level implementation, and relaxing of NPIs, which document the type and date of NPI implementation (e.g., school closings, restaurant closings, stay at home order, cloth masks), who is covered (older persons, non-essential workers), as well as when specific NPIs are relaxed. We will characterize NPI implementation according to indices of stringency developed by others.[19]

County-level physical distancing. Stay-at-home orders and other measures have greatly reduced population mobility in many areas.[20] We will operationalize physical distancing using a proxy—changes in mobility at the county level relative to the timing of first cases and deaths in each county—to classify counties as having *achieved* physical distancing early or late and to assess the influence of *relaxing* physical distancing measures (relative to nadir). We will use county-level data on mobility, updated daily, from Descartes Labs (posted on GitHub)[21]. These data include mobility calculated using GPS data from 'a collection of mobile devices reporting consistently throughout' each day.[22] The maximum distance moved in kilometers is calculated daily for each person, and aggregated up to the county level median (or other aggregate

metric). We will use the following metrics: 1. M50 - the median of the max-distance mobility for all samples in each county; and 2. M50I (m50 index) - the percent of normal M50 in the region, with normal M50 defined during Feb 17, 2020 to March 7, 2020. M50, and to a lesser degree M50I, will be highly influenced by the proximity/density of resources (e.g., supermarkets).

Planned analyses. We will integrate time-updated publicly available county-level data on mobility[22], SARS/COV2 diagnoses, and COVID-19 deaths[23] with our longitudinal C^3 cohort data to determine the impact of NPI implementation on SARS/COV2 outcomes. Among SARS/COV2 seropositive individuals, we will estimate the proportion with asymptomatic and mild disease using their previously reported data on symptoms consistent with COVID-19, weighted to the US adult population using age, sex, and race/ethnicity stratification. To assess whether seropositivity for SARS/COV2 is protective against new disease, we will compare the incidence of COVID-like disease (any and severe) among persons previously identified as seropositive to that of persons previously identified as seronegative, geographically matched within areas where SARS/COV2 transmission remains active.

Figure 2: Enrollment in the CHASING COVID Cohort



Data management

All data were imported and cleaned in R and SAS (V9.4). Data were geocoded based on a self-reported ZIP code. Maps were created in ArcGIS 10.7.

Ethical Approval

The C^3 study protocol was approved by the Institutional Review Board at the City University of New York (CUNY) Graduate School for Public Health and Health Policy.

RESULTS

Cohort Eligibility and Recruitment

Among the N=8,711 participants who were eligible, 82% (N = 7,125) completed the survey, and 81% (7,070) left an email address for future study-follow-up (Figure 2).

Baseline Characteristics of C^3 Stratified by Age Characteristics

Figure 3. Geographic distribution of CHASING COVID Cohort participants by county of residence, N=7,070



The final cohort of 7,070 was geographically diverse (Figure 3), with participants from all 50 states, the District of Columbia, Puerto Rico and Guam. The median age of participants was 42 years (interquartile range: 31, 58); 61% were aged 18-49 (including 5% <21 years (N=345)), 16% were aged 50-59, and 23% were aged 60 years or older (Table 1). Just over half (51%) were male, 14% were Hispanic, 11% black non-Hispanic, 5% Asian or Pacific Islander, and 67% white non-Hispanic. A majority were currently employed (53%), 18% were retired, 16% were out of work, and 9% were students.

More than half (54%) were at increased risk for COVID-19 illness should they become infected with SARS/COV2 on the basis of age (60+), reporting an underlying health condition (chronic lung disease, asthma (current), type 2 diabetes, serious heart condition, kidney disease, or an immunocompromised status), or daily smoking (Table 2). The proportion of

persons with an underlying health condition increased with age category (28% among 18-49 year olds and 44% among 60+), and the proportion of daily smokers decreased with increasing age category (20% and 11%, respectively).

Among 5,403 participants that completed the updated version of the baseline assessment that included questions on essential employment (participants could select more than one employment category), 24% reported being a frontline worker (healthcare or other essential workers) (Table 2, Figure 1). By employment category, 9% were healthcare workers, 5% were healthcare workers who screened or cared for COVID-19 patients, 11% were in delivery services (e.g., food) and

Table 2. Characteristics of Chasing Covid Cohort At Baseline

	Total		18-48		50-59		60+		Chi-Square
	N	%	N	%	N	%	N	%	P-value
Total	7,070	100	4,322	100	1,109	100	1,639	100	
Age (Median, IQR)	42 (31, 58)		34 (27, 41)		54 (52, 57)		68 (64, 72)		
Gender									**<0.0001**
Male	3,619	51	2,360	55	543	49	716	44	
Female	3,234	46	1,775	41	552	50	907	55	
Non-Binary	217	3	187	4	14	1	16	1	
Race/Ethnicity									**<0.0001**
Hispanic	981	14	788	18	109	10	84	5	
Black Non-Hispanic	750	11	562	13	95	9	93	6	
Asian\Pacific Islander	346	5	301	7	18	2	27	2	
White Non-Hispanic	4,706	67	2,503	58	834	75	1,369	84	
Other	287	4	168	4	53	5	66	4	
Employment									**<0.0001**
Employed	3,709	52	2,637	61	655	59	417	25	
Out of work	1,163	16	816	19	215	19	132	8	
Homemaker	347	5	220	5	88	8	39	2	
Student	610	9	596	14	10	1	4	0	
Retired	1,241	18	53	1	141	13	1,047	64	
Income ($)									**<0.0001**
<50,000	3,332	47	2,000	46	496	45	836	51	
50,000 to 99,999	1,688	24	1,009	23	275	25	404	25	
100,000+	1,614	23	987	23	289	26	338	21	
Missing	436	6	326	8	49	4	61	4	
Region									**<0.01**
Midwest	1,431	20	835	19	245	22	351	21	
Northeast	1,795	25	1,127	26	262	24	406	25	
South	2,281	32	1,381	32	364	33	536	33	
West	1,531	22	968	22	230	21	333	20	
US Dependent	32	0	11	0	8	1	13	1	
Urban Area	**2,780**	**39**	**1,953**	**45**	**384**	**35**	**443**	**27**	**<0.0001**
High Risk for Severe COVID19 Illness[1]	**3,805**	**54**	**1,641**	**38**	**525**	**47**	**1,639**	**100**	**<0.0001**
Any Underlying Health Condition[2]	**2,334**	**33**	**1,197**	**28**	**419**	**38**	**718**	**44**	**<0.0001**
Daily Smoker[3]	**1,238**	**18**	**846**	**20**	**213**	**19**	**179**	**11**	**<0.0001**
Survey Version 2.0 (Total)	5,403	100	3,105	100	855	100	1,443	100	
Essential Workers[4]	**1,305**	**24**	**877**	**28**	**190**	**22**	**238**	**16**	**<0.0001**
All Healthcare Workers (HCW)[4]	471	9	359	12	57	7	55	4	<0.0001
HCW Who Screen or Care for COVID19 Patients[4]	284	5	234	8	28	3	22	2	<0.0001
Law Enforcement[4]	90	2	62	2	19	2	9	1	0.0013
Emergency Response[4]	55	1	35	1	7	1	13	1	0.6373
Delivery Services (e.g., food)[4]	594	11	361	12	93	11	140	10	0.1539
Transportation (e.g., taxi or airline)[4]	219	4	149	5	31	4	39	3	0.0030

1. High risk for severe illness included people 60 years or older or reporting any underlying health condition, or daily smoking

2. Any underlying health condition includes people who reported chronic lung disease, asthma (current), type 2 diabetes, serious heart condition (history of MI, angina, or CHD), kidney disease, HIV or immunocompromised

3. People who report they smoke cigarettes or e-cigarettes daily

4. Essential worker questions were asked of 5,418 persons. Participants could select more than one essential worker category

Table: CUNY ISPH • Source: CUNY ISPH • Created with Datawrapper

4% were in transportation (e.g., taxis). The proportion of persons employed in frontline work decreased with increasing category of age.

NPI / Physical Distancing Behaviors Stratified by Age Categories

A high proportion of participants reported avoiding large groups with >20 people in the past two weeks and avoiding handshakes or hugs (93% and 92%, respectively) (Table 3). Nearly half (49%) reported working from home. A majority reported wearing gloves (56%) and masks (58%), and these proportions significantly increased with age (54% of 18-49 year olds wore gloves versus 61% of 60+, and 54% of 18-49 year olds wore masks versus 68% of 60+, p for chi-square: <0.001 for each comparison). Almost one in six (15%) participants reported stockpiling personal protective equipment and 41% reported stockpiling food. The proportion of participants who reported stockpiling decreased significantly with increasing age categories (17% of 18-49 year olds stockpiled PPE versus 13% of 60+, and 47% of 18-49 year olds stockpiled food versus 31% of 60+, p<0.001 for each comparison).

Table 3. Behaviors and Symptoms by Age Category of Chasing Covid Cohort At Baseline

	Total		18-48		50-59		60+		Chi-Square
	N	%	N	%	N	%	N	%	P-value
Total	7,070	100	4,322	100	1,109	100	1,639	100	
Behaviors - Past 2 Weeks									
Avoided Groups >20	6,574	93	3,998	93	1,038	94	1,538	94	0.03
Avoided Handshakes	6,495	92	3,921	91	1,041	94	1,533	94	<0.01
Worked from Home	3,477	49	2,587	60	478	43	412	25	<0.0001
Wore Gloves	3,968	56	2,336	54	635	57	997	61	<0.0001
Wore Masks	4,118	58	2,354	54	647	58	1,117	68	<0.0001
Stockpiled Personal Protective Equipment	1,059	15	723	17	123	11	213	13	<0.0001
Stockpiled Food	2,908	41	2,020	47	378	34	510	31	<0.0001
Quarantined	5,156	73	3,222	75	783	71	1,151	70	0.04
Symptoms - Past 2 Weeks									
COVID-like symptoms: cough, fever, or shortness of breath	1,436	20	1,012	23	203	18	221	13	<0.0001
New Cough	839	12	602	14	130	12	107	7	<0.0001
Fever	473	7	371	9	62	6	40	2	<0.0001
Shortness of Breath	625	9	387	9	96	9	142	9	0.91
Coughing Blood	23	0	19	0	3	0	1	0	0.07

Table: CUNY ISPH • Source: CUNY ISPH • Created with Datawrapper

COVID-19 symptoms and care outcomes

One in five (20% or N = 1,436) reported any COVID-like symptoms prior to C^3 enrollment (cough, fever or shortness of breath) and this decreased significantly with age (23% versus 13% among 18-49 and 60+ year olds, respectively and p<0.001) (Table 3). The most common symptoms reported were new cough (12%) followed by shortness of breath (9%) and fever (7%).

Table 4. Chasing Covid Cohort Care Outcomes Stratified by Risk for Severe COVID19 Illness

			High Risk for Severe COVID19 Illness[1]				
	Total		No		Yes		Chi-Square
	N	%	N	%	N	%	P-value[2]
All with COVID-like Symptoms: cough, fever or shortness of breath	1,436	100	574	100	862	100	
Saw Physician							**<0.0001**
Yes	555	39	162	28	393	46	
No	875	61	409	71	466	54	
Missing	6	0	3	1	3	0	
Hospitalized							**<0.0001**
Yes	166	12	10	2	156	18	
No	1,266	88	562	98	704	82	
Missing	4	0	2	0	2	0	
All C^3 Participants	7,070	100	3,265	100	3,805	100	
Tested for COVID19							**<0.0001**
Yes	368	5	103	3	265	7	
No, but tried to be tested	551	8	256	8	295	8	
No, did not need to be tested	6,052	86	2,864	88	3,188	84	
Do not know	99	1	42	1	57	2	
COVID19 Diagnosis							**<0.0001**
Yes	191	3	26	1	165	4	
No	234	3	96	3	138	4	
Unsure of Diagnosis	42	1	23	1	19	1	
Missing	6,603	93	3,120	96	3,483	92	

[1] Increased risk for COVID-19 illness based on age (60+), reporting an underlying health condition (chronic lung disease, asthma (current), type 2 diabetes, serious heart condition, kidney disease, or an immunocompromised status), daily smoking

[2] Fishers exact test was used as needed

Table: CUNY ISPH • Source: CUNY ISPH • Created with Datawrapper

Among the 20% of participants reporting COVID-like symptoms (N = 1,436), 39% (N = 555) said they called or saw a physician/healthcare professional and 12% (N = 166) were hospitalized (Table 4). Compared to participants at lower risk for COVID-19 illness, participants with higher risk for severe COVID-19 illness were more likely to report seeing a physician or hospitalization (28% versus 46% and 2% versus 18%, respectively and $p < 0.001$ for each comparison). Among all participants, 5% (N = 368) reported being tested for COVID-19 and 3% (N = 191) reported receiving a COVID-19 diagnosis. Participants at higher risk for COVID-19 illness were significantly more likely to report testing or receiving a diagnosis than participants at lower risk for severe COVID-19 illness (testing: 7% versus 3% and diagnosis: 4% versus 1%, respectively and $p<0.001$ for each comparison).

DISCUSSION

The C^3 study of 7,070 persons from all 50 US states, the District of Columbia, Puerto Rico and Guam was rapidly established in the middle of the SARS/COV2 upswing in the US. The C^3 cohort is geographically and socio-demographically diverse, and includes participants from many active hotspots during the recruitment period (March 28-April 20, 2020), as well as frontline health care workers and other essential employees, and individuals who are vulnerable to severe outcomes associated with SARS/COV2 infection.

At the baseline assessment, nearly one in five reported having had recent COVID-like symptoms. Among those reporting COVID-like symptoms, 38% reported seeing a health care provider and 12% reported being hospitalized. A small proportion of C^3 participants reported being tested for or diagnosed with SARS/COV2 (5% and 3%, respectively), and participants with elevated risk for COVID-19 illness were more likely to report seeking care, hospitalization, and testing than participants without elevated risk. Limitations of serological assays notwithstanding, recent cross-sectional serosurveys done prior to the relaxing of physical

distancing have reported seroprevalence estimates ranging from 3% in CA to 21% in NYC.[24–26] Many in the C^3 cohort are likely to have serologic evidence of prior SARS/COV2 infection as of the Month 1 follow-up assessment. Those that are seronegative at Month 1 may be at high risk for seroconversion between Months 1 and 3, given ongoing transmission in many areas, and the expectation of physical distancing measures being relaxed in the coming months. When this occurs, many areas will also be implementing enhanced testing, contact tracing, and quarantine. The C^3 Study has the potential to monitor and assess the uptake and impact of these key strategies that are part of the public health response to control and mitigate the SARS/COV2 pandemic in the U.S.

Strengths of the C^3 study include its prospective (vs. cross-sectional) design, allowing direct observation of seroconversions and incident COVID disease among those who were unexposed and/or disease free. The longitudinal design also allows prospective estimation of the incidence of COVID disease among those with antibodies to SARS/COV2, allowing a rapid assessment -- in the midst of a pandemic -- of the extent to which SARS/COV2 antibodies offer short-term protection against subsequent disease. Prospective studies, which by definition follow the same individuals forward in time, are complementary to and offer some strengths over cross sectional studies, especially in the context of rapidly evolving emergencies and the associated public health response. While repeat cross-sectional surveys are valuable in a pandemic, including their ability to assess trends in many important outcomes, they cannot assess what factors may influence change over time in an individual. Cross-sectional studies also by definition will exclude persons who are in the hospital or who have died.

We are using assessment strategies designed to minimize their assessment effects, as well as objective biological indicators. Studies requiring human contact can cause participants to under-report sensitive health behaviors and to adopt behaviors that make them less

representative of the populations from which they were drawn. Studies involving high levels of contact may induce behavior change by repeatedly engaging participants outside of their natural context, artificially biasing results[27,28] and reducing generalizability.[29]

The C^3 study has limitations worth noting, as they inform what can and cannot be assessed. First, C^3 will be unable to provide representative estimates of prevalence and incidence. Second, we will underestimate hospitalizations and are unable to capture deaths due to COVID or other causes. Most research studies, including ours, deployed in the middle of a pandemic will, by definition, produce some biased estimates since they will not include information on persons who died from COVID, were hospitalized with COVID prior to or during recruitment, or were too sick to participate in a research study at the time of recruitment. From published studies, we will assess bias in our estimates due to these factors and adjust them accordingly. Third, we will be unable to conduct state or county specific analyses, except for a few localities with high participation (e.g., New York and California). Finally, we do not yet know the retention rate or the acceptance rate for specimen collection. However, participants may be more motivated to participate in follow-up, given the active threat and novelty of the COVID-19 pandemic and its ongoing impact on individuals and communities.

We considered the strengths and weaknesses of several different study designs and methodologic features when designing and launching the C^3. Ultimately, we chose a design that prioritized our ability to rapidly answer key epidemiologic questions and enroll a geographically and socio-demographically diverse sample of individuals. We considered whether a probability sample of households with a telephone phone interview should be leveraged, given the potential to use a known sampling frame which would facilitate estimates that may be more population representative. However, given the need for rapid information and knowledge generation, we chose to recruit participants from online settings, and enrolled >7,000 people in 3 weeks.

Although our sample is not representative of the entire US population, it is geographically representative and socio-demographically diverse. Our study will complement other efforts to address similar research questions, such as the NIH's planned serosurvey.[30] Indeed, it will be important to assess if online vs. conventional recruitment methods reach similar conclusions.

Our approach employs protocols for overcoming common pitfalls of fully online studies (e.g., repeat/duplicate participation). Our online, volunteer recruitment approach allows us to sample individuals who may not be reached by traditional telephone recruitment approaches, which can have very low response rates. As part of our enrollment procedures, we record IP address, email addresses, participant contact information, and require participants to have valid US mailing addresses (required to receive an at-home SARS/COV2 specimen collection kit). Participants will be "known" to the research team (name, email, address), thus averting some of the traditional shortcomings of online-only studies (particularly anonymous, cross-sectional online studies).

Data sharing

We plan to rapidly produce manuscripts, which will be simultaneously submitted to MedRxiv[75] and leading scientific journals for peer review. To increase the impact of our work, we will also post a deidentified, HIPAA compliant, public use version of our baseline and follow-up data on GitHub.[76] Data will be presented as flat text files (CSV) formatted for compatibility with the New York Times county-level longitudinal case load dataset[3], including date, county, state, and fips code. A GitHub Actions script will perform weekly updates of the repository and its associated GitHub Pages site, automatically incorporating all new submissions from the previous week. Finally, we will provide direct feedback to our cohort and other stakeholders who have signed up for updates via our C^3 newsletter.[31]

Conclusion

A geographically and socio-demographically diverse group of participants was rapidly enrolled in the C^3 during the upswing of the SARS/COV2 pandemic. Strengths of the C^3 include the potential for direct observation of, and risk factors for, seroconversions and incident COVID disease (among those with or without antibodies to SARS/COV2) in areas of active transmission. The C^3 Study has the potential to monitor and assess the uptake and impact of the public health response to control and mitigate the SARS/COV2 pandemic in the US.

FUNDING

Funding for this project is provided by the CUNY Institute for Implementation Science in Population Health (cunyisph.org) and the COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy.

Tables

Table 1. Realms of Measurement in the Chasing Covid Cohort

At baseline and follow-up assessments

	Baseline	Month 1 follow-up assessment
Sociodemographics	✔	
Household size and age distribution	✔	
Pre-existing/co-morbid conditions	✔	
Smoking and vaping behaviors	✔	
Employment status	✔	✔
Essential employee status[1]	✔	✔
Health care access and insurance status	✔	✔
Recent COVID-related symptoms	✔	✔
Saw or called physician/HCP for COVID-like symptoms	✔	✔
Recent COVID diagnosis	✔	✔
Recent SARS/COV2 testing	✔	✔
Recent hospitalization for COVID-like symptoms	✔	✔
NPI uptake and other precautions	✔	✔
Anxiety symptoms (GAD-7)	✔	✔
Risk perception about COVID	✔	✔
Influence of social media on COVID knowledge and beliefs	✔	✔
Trust in government to prioritize safety		✔
Serology (SARS/COV2 IgM and IgG)		✔
Food and housing security		✔
Depressive symptoms (PHQ2)		✔
Social support		✔
IPV		✔
Substance use		✔
Unhealthy drinking (Audit-C)		✔
Willingness to donate plasma to help others		✔

[1]Frontline health care workers, hospital staff, first responders, grocery clerks, delivery workers

Table: CUNY ISPH • Source: CUNY ISPH • Created with Datawrapper

Table 2. Characteristics of Chasing Covid Cohort At Baseline

	Total		18-48		50-59		60+		Chi-Square
	N	%	N	%	N	%	N	%	P-value
Total	7,070	100	4,322	100	1,109	100	1,639	100	
Age (Median, IQR)	42 (31, 58)		34 (27, 41)		54 (52, 57)		68 (64, 72)		
Gender									**<0.0001**
Male	3,619	51	2,360	55	543	49	716	44	
Female	3,234	46	1,775	41	552	50	907	55	
Non-Binary	217	3	187	4	14	1	16	1	
Race/Ethnicity									**<0.0001**
Hispanic	981	14	788	18	109	10	84	5	
Black Non-Hispanic	750	11	562	13	95	9	93	6	
Asian\Pacific Islander	346	5	301	7	18	2	27	2	
White Non-Hispanic	4,706	67	2,503	58	834	75	1,369	84	
Other	287	4	168	4	53	5	66	4	
Employment									**<0.0001**
Employed	3,709	52	2,637	61	655	59	417	25	
Out of work	1,163	16	816	19	215	19	132	8	
Homemaker	347	5	220	5	88	8	39	2	
Student	610	9	596	14	10	1	4	0	
Retired	1,241	18	53	1	141	13	1,047	64	
Income ($)									**<0.0001**
<50,000	3,332	47	2,000	46	496	45	836	51	
50,000 to 99,999	1,688	24	1,009	23	275	25	404	25	
100,000+	1,614	23	987	23	289	26	338	21	
Missing	436	6	326	8	49	4	61	4	
Region									**<0.01**
Midwest	1,431	20	835	19	245	22	351	21	
Northeast	1,795	25	1,127	26	262	24	406	25	
South	2,281	32	1,381	32	364	33	536	33	
West	1,531	22	968	22	230	21	333	20	
US Dependent	32	0	11	0	8	1	13	1	
Urban Area	**2,780**	**39**	**1,953**	**45**	**384**	**35**	**443**	**27**	**<0.0001**
High Risk for Severe COVID19 Illness[1]	**3,805**	**54**	**1,641**	**38**	**525**	**47**	**1,639**	**100**	**<0.0001**
Any Underlying Health Condition[2]	**2,334**	**33**	**1,197**	**28**	**419**	**38**	**718**	**44**	**<0.0001**
Daily Smoker[3]	**1,238**	**18**	**846**	**20**	**213**	**19**	**179**	**11**	**<0.0001**
Survey Version 2.0 (Total)	5,403	100	3,105	100	855	100	1,443	100	
Essential Workers[4]	**1,305**	**24**	**877**	**28**	**190**	**22**	**238**	**16**	**<0.0001**
All Healthcare Workers (HCW)[4]	471	9	359	12	57	7	55	4	<0.0001
HCW Who Screen or Care for COVID19 Patients[4]	284	5	234	8	28	3	22	2	<0.0001
Law Enforcement[4]	90	2	62	2	19	2	9	1	0.0013
Emergency Response[4]	55	1	35	1	7	1	13	1	0.6373
Delivery Services (e.g., food)[4]	594	11	361	12	93	11	140	10	0.1539
Transportation (e.g., taxi or airline)[4]	219	4	149	5	31	4	39	3	0.0030

1. High risk for severe illness included people 60 years or older or reporting any underlying health condition, or daily smoking

2. Any underlying health condition includes people who reported chronic lung disease, asthma (current), type 2 diabetes, serious heart condition (history of MI, angina, or CHD), kidney disease, HIV or immunocompromised

3. People who report they smoke cigarettes or e-cigarettes daily

4. Essential worker questions were asked of 5,418 persons. Participants could select more than one essential worker category

Table: CUNY ISPH • Source: CUNY ISPH • Created with Datawrapper

Table 3. Behaviors and Symptoms by Age Category of Chasing Covid Cohort At Baseline

	Total		18-48		50-59		60+		Chi-Square
	N	%	N	%	N	%	N	%	P-value
Total	7,070	100	4,322	100	1,109	100	1,639	100	
Behaviors - Past 2 Weeks									
Avoided Groups >20	6,574	93	3,998	93	1,038	94	1,538	94	0.03
Avoided Handshakes	6,495	92	3,921	91	1,041	94	1,533	94	<0.01
Worked from Home	3,477	49	2,587	60	478	43	412	25	<0.0001
Wore Gloves	3,968	56	2,336	54	635	57	997	61	<0.0001
Wore Masks	4,118	58	2,354	54	647	58	1,117	68	<0.0001
Stockpiled Personal Protective Equipment	1,059	15	723	17	123	11	213	13	<0.0001
Stockpiled Food	2,908	41	2,020	47	378	34	510	31	<0.0001
Quarantined	5,156	73	3,222	75	783	71	1,151	70	0.04
Symptoms - Past 2 Weeks									
COVID-like symptoms: cough, fever, or shortness of breath	1,436	20	1,012	23	203	18	221	13	<0.0001
New Cough	839	12	602	14	130	12	107	7	<0.0001
Fever	473	7	371	9	62	6	40	2	<0.0001
Shortness of Breath	625	9	387	9	96	9	142	9	0.91
Coughing Blood	23	0	19	0	3	0	1	0	0.07

Table: CUNY ISPH • Source: CUNY ISPH • Created with Datawrapper

Table 4. Chasing Covid Cohort Care Outcomes Stratified by Risk for Severe COVID19 Illness

			High Risk for Severe COVID19 Illness[1]				
	Total		No		Yes		Chi-Square
	N	%	N	%	N	%	P-value[2]
All with COVID-like Symptoms: cough, fever or shortness of breath	1,436	100	574	100	862	100	
Saw Physician							**<0.0001**
Yes	555	39	162	28	393	46	
No	875	61	409	71	466	54	
Missing	6	0	3	1	3	0	
Hospitalized							**<0.0001**
Yes	166	12	10	2	156	18	
No	1,266	88	562	98	704	82	
Missing	4	0	2	0	2	0	
All C³ Participants	7,070	100	3,265	100	3,805	100	
Tested for COVID19							**<0.0001**
Yes	368	5	103	3	265	7	
No, but tried to be tested	551	8	256	8	295	8	
No, did not need to be tested	6,052	86	2,864	88	3,188	84	
Do not know	99	1	42	1	57	2	
COVID19 Diagnosis							**<0.0001**
Yes	191	3	26	1	165	4	
No	234	3	96	3	138	4	
Unsure of Diagnosis	42	1	23	1	19	1	
Missing	6,603	93	3,120	96	3,483	92	

[1] Increased risk for COVID-19 illness based on age (60+), reporting an underlying health condition (chronic lung disease, asthma (current), type 2 diabetes, serious heart condition, kidney disease, or an immunocompromised status), daily smoking

[2] Fishers exact test was used as needed

Table: CUNY ISPH • Source: CUNY ISPH • Created with Datawrapper

Figure 1. Cumulative Chasing Covid Cohort Enrollment and Cumulative COVID19 Deaths in the US



Chart: CUNY ISPH • Source: New York Times and CUNY ISPH • Created with Datawrapper

Figure 2: Enrollment in the CHASING COVID Cohort



Figure 3. Geographic distribution of CHASING COVID Cohort participants by county of residence, N=7,070



REFERENCES

1. Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Covid-19—studies needed. N Engl J Med [Internet] 2020;382(13):1194–6. Available from: https://www.nejm.org/doi/full/10.1056/NEJMp2002125

2. Grov C, Westmoreland DA, Carneiro PB, et al. Recruiting vulnerable populations to participate in HIV prevention research: findings from the Together 5000 cohort study [Internet]. Annals of Epidemiology. 2019;35:4–11. Available from: http://dx.doi.org/10.1016/j.annepidem.2019.05.003

3. Nash D, Stief M, MacCrate C, et al. A Web-Based Study of HIV Prevention in the Era of Pre-Exposure Prophylaxis Among Vulnerable HIV-Negative Gay and Bisexual Men, Transmen, and Transwomen Who Have Sex With Men: Protocol for an Observational Cohort Study [Internet]. JMIR Research Protocols. 2019;8(9):e13715. Available from: http://dx.doi.org/10.2196/13715

4. Grov C, Westmoreland D, Rendina J, Nash D. Seeing is believing? Unique capabilities of internet-only studies as a tool for implementation research on HIV prevention for men who have sex with men: A review of studies and methodological considerations. JAIDS 2019;In press.

5. Qualtrics XM - Experience Management Software [Internet]. Qualtrics. 2015 [cited 2020 Apr 26];Available from: https://www.qualtrics.com/

6. COVID-19 United States Cases by County [Internet]. Johns Hopkins Coronavirus Resource Center. [cited 2020 Apr 23];Available from: https://coronavirus.jhu.edu/us-map

7. Santibanez TA, Singleton JA, Santibanez SS, Wortley P, Bell BP. Socio-demographic differences in opinions about 2009 pandemic influenza A (H1N1) and seasonal influenza vaccination and disease among adults during the 2009--2010 influenza season. Influenza Other Respi Viruses [Internet] 2013;7(3):383–92. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1750-2659.2012.00374.x

8. Kumar S, Quinn SC, Kim KH, Daniel LH, Freimuth VS. The impact of workplace policies and other social factors on self-reported influenza-like illness incidence during the 2009 H1N1 pandemic. Am J Public Health [Internet] 2012;102(1):134–40. Available from: http://dx.doi.org/10.2105/AJPH.2011.300307

9. Niles MT, Neff R, Biehl E, Bertmann F, Morgan EH, Wentworth T. Food Access and Security During Coronavirus Survey- Version 1.0 [Internet]. 2020;Available from: https://doi.org/10.7910/DVN/RQ6NMG

10. How To Collect Blood with Dry Blood Spot Kit - Molecular Testing Labs [Internet]. Molecular Testing Labs. [cited 2020 Apr 13];Available from: https://moleculartestinglabs.com/how-to-collect/

11. Home - Molecular Testing Labs [Internet]. Molecular Testing Labs. [cited 2020 Apr 26];Available from: https://moleculartestinglabs.com/

12. Drew DA, Nguyen LH, Steves CJ, et al. Rapid implementation of mobile technology for real-time epidemiology of COVID-19. medRxiv [Internet] 2020 [cited 2020 Apr 11];2020.04.02.20051334. Available from: https://www.medrxiv.org/content/10.1101/2020.04.02.20051334v1

13. CDC. Coronavirus Disease 2019 (COVID-19) – Symptoms [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2020 Apr 26];Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html

14. Maruish ME. Handbook of Psychological Assessment in Primary Care Settings [Internet]. Routledge; 2017. Available from: https://play.google.com/store/books/details?id=7Z-8DgAAQBAJ

15. Thombs BD, Benedetti A, Kloda LA, et al. The diagnostic accuracy of the Patient Health Questionnaire-2 (PHQ-2), Patient Health Questionnaire-8 (PHQ-8), and Patient Health Questionnaire-9 (PHQ-9) for detecting major depression: protocol for a systematic review and individual patient data meta-analyses [Internet]. Systematic Reviews. 2014;3(1).

Available from: http://dx.doi.org/10.1186/2046-4053-3-124

16. Tiet QQ, Leyva Y, Moos RH, Smith B. Diagnostic accuracy of a two-item screen for drug use developed from the alcohol, smoking and substance involvement screening test (ASSIST) [Internet]. Drug and Alcohol Dependence. 2016;164:22–7. Available from: http://dx.doi.org/10.1016/j.drugalcdep.2016.03.029

17. McNeely J, Strauss SM, Wright S, et al. Test-retest reliability of a self-administered Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in primary care patients. J Subst Abuse Treat [Internet] 2014;47(1):93–101. Available from: http://dx.doi.org/10.1016/j.jsat.2014.01.007

18. Seong JH, Lee CH, Do HJ, et al. Performance of the AUDIT Alcohol Consumption Questions (AUDIT-C) and AUDIT-K Question 3 Alone in Screening for Problem Drinking. Korean J Fam Med [Internet] 2009 [cited 2020 Apr 25];30(9):695–702. Available from: https://www.kjfm.or.kr/journal/view.php?number=132

19. Coronavirus Government Response Tracker [Internet]. [cited 2020 Apr 14];Available from: https://www.bsg.ox.ac.uk/research/research-projects/coronavirus-government-response-tracker

20. Mobility - Descartes Labs [Internet]. Descartes Labs. [cited 2020 Apr 25];Available from: https://www.descarteslabs.com/mobility/

21. DL-COVID-19 [Internet]. Github; [cited 2020 Apr 11]. Available from: https://github.com/descarteslabs/DL-COVID-19

22. Mobility - Descartes Labs [Internet]. Descartes Labs. [cited 2020 Apr 11];Available from: https://www.descarteslabs.com/mobility/

23. An ongoing repository of data on coronavirus cases and deaths in the U.S. - nytimes/covid-19-data [Internet]. Github; [cited 2020 Apr 11]. Available from: https://github.com/nytimes/covid-19-data

24. Cuomo Says 21% of Those Tested in N.Y.C. Had Virus Antibodies [Internet]. New York Times. 2020 [cited 2020 Apr 25];Available from: https://www.nytimes.com/2020/04/23/nyregion/coronavirus-new-york-update.html

25. Bendavid E, Mulaney B, Sood N, et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California. medRxiv [Internet] 2020;Available from: https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v1.abstract

26. USC-LA County Study: Early Results of Antibody Testing Suggest Number of COVID-19 Infections Far Exceeds Number of Confirmed Cases in Los Angeles County [Internet]. [cited 2020 Apr 25];Available from: http://publichealth.lacounty.gov/phcommon/public/media/mediapubhpdetail.cfm?prid=2328

27. McCambridge J, Kypri K, Elbourne D. Research participation effects: a skeleton in the methodological cupboard [Internet]. Journal of Clinical Epidemiology. 2014;67(8):845–9.

Available from: http://dx.doi.org/10.1016/j.jclinepi.2014.03.002

28. McCambridge J, de Bruin M, Witton J. The Effects of Demand Characteristics on Research Participant Behaviours in Non-Laboratory Settings: A Systematic Review [Internet]. PLoS ONE. 2012;7(6):e39116. Available from: http://dx.doi.org/10.1371/journal.pone.0039116

29. Bouchet C, Guillemin F, Briançon S. Nonspecific effects in longitudinal studies: Impact on quality of life measures [Internet]. Journal of Clinical Epidemiology. 1996;49(1):15–20. Available from: http://dx.doi.org/10.1016/0895-4356(95)00540-4

30. NIH Begins Study to Quantify Undetected Cases of Coronavirus Infection | NIH: National Institute of Allergy and Infectious Diseases [Internet]. [cited 2020 Apr 12];Available from: https://www.niaid.nih.gov/news-events/nih-begins-study-quantify-undetected-cases-coronavirus-infection

31. CHASING COVID Study Updates | CUNY ISPH [Internet]. CUNY ISPH. [cited 2020 Apr 25];Available from: https://cunyisph.org/chasing-covid-study-updates/